2014
DOI: 10.1097/mbc.0000000000000039
|View full text |Cite
|
Sign up to set email alerts
|

Fibrinogen geneva II

Abstract: Congenital dysfibrinogenemias are characterized by biosynthesis of a structurally abnormal fibrinogen molecule that exhibits reduced functional levels compared with the level of fibrinogen antigen. To date a large number of mutations have been identified in patients with dysfibrinogenemia. Mutations occurring at the thrombin cleavage site (Arg16-Gly17 in the mature alpha-chain) at the amino-terminal end of the fibrinogen alpha chain are a common cause of the disease. These mutations causing abnormal fibrin pol… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
2
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 13 publications
1
2
0
Order By: Relevance
“…[7] Similar results were reported by Casini et al [19] : FGA mutations affecting residue Arg16 (i.e., Arg16His and Arg16Cys) at the FpA thrombin cleavage site were frequent in 13.9% and 8.9% of patients, respectively. [24] The results indicate that the substitution of the Aα-chain residue Arg16His can prevent thrombin cleavage of the scissile Aα Arg16-Gly17 bond, thus delaying the release of FpA and disrupting of the initial alignment of fibrin monomers into protofibrils, and then these changes can impair the subsequent fibrin clot formation.…”
Section: Discussionsupporting
confidence: 80%
See 1 more Smart Citation
“…[7] Similar results were reported by Casini et al [19] : FGA mutations affecting residue Arg16 (i.e., Arg16His and Arg16Cys) at the FpA thrombin cleavage site were frequent in 13.9% and 8.9% of patients, respectively. [24] The results indicate that the substitution of the Aα-chain residue Arg16His can prevent thrombin cleavage of the scissile Aα Arg16-Gly17 bond, thus delaying the release of FpA and disrupting of the initial alignment of fibrin monomers into protofibrils, and then these changes can impair the subsequent fibrin clot formation.…”
Section: Discussionsupporting
confidence: 80%
“…Many studies show that 1 characteristic of CD is normal fibrinogen antigen levels associated with disproportionately low functional activity. [7,8] The vast majority of cases are the result of heterozygous missense mutations in coding region of 1 of the 3 fibrinogen genes (FGA, FGB, or FGG). [9] Molecular defects are usually single-base mutations, leading to alterations in the release of fibrinopeptide, fibrin polymerization, fibrin cross-linking, or fibrinolysis of the fibrinogen.…”
Section: Introductionmentioning
confidence: 99%
“…In the first issue of 2024, STH republished the first paper that STH ever published, on the molecular structure of fibrinogen, 22 with an accompanying Commentary from Alessandro Casini and Marguerite Neerman-Arbez. 23 In the current issue of STH, we are republishing the most cited manuscript from STH according to Web of Science, 24 and an accompanying Commentary from authors. 25…”
Section: Tablementioning
confidence: 99%